MedTrace Logo

NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors

NCT05354323 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-06-26

No results posted yet for this study

Summary

NECVAX-NEO1 in addition to anti-PD-1 or anti-PD-L1 monoclonal antibody checkpoint inhibitor monotherapy in n=6 patients with solid tumors

Conditions

  • Solid Tumors, Adult

Interventions

BIOLOGICAL

NECVAX-NEO1

Oral Ty21a based T-cell vaccination, personalized patient-individual NECVAX-NEO1 constructs containing a eukaryotic expression plasmid encoding for a series of selected neoantigen epitopes

Sponsors & Collaborators

  • NEC OncoImmunity AS

    lead INDUSTRY

Principal Investigators

  • Elona Juozaityte, MD · Hospital of Lithuanian University of Health Sciences Kauno Klinikos

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-05
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Lithuania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05354323 on ClinicalTrials.gov